NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

NAMS

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/20

07:27 am

nams

NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.

Low Report

NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.

Report

2/19

03:08 pm

nams

NewAmsterdam Pharma (NASDAQ:NAMS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Low Report

NewAmsterdam Pharma (NASDAQ:NAMS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.

Report

2/19

09:31 am

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

2/19

09:31 am

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

2/19

08:42 am

nams

NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.

Low Report

NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.

Report

2/19

08:42 am

nams

NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.

Low Report

NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Guggenheim.

Report

2/18

12:32 pm

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

2/18

12:32 pm

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

1/21

09:41 am

nams

Rating for NAMS

Medium Report

Rating for NAMS

Report

1/21

09:41 am

nams

Rating for NAMS

Medium Report

Rating for NAMS

Report

1/21

07:17 am

nams

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medium Report

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

1/21

07:17 am

nams

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medium Report

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Report

1/6

07:17 am

nams

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.

Low Report

NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.

Report

12/16

12:28 pm

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

12/2

01:14 pm

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

12/2

01:14 pm

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

12/2

01:14 pm

nams

Rating for NAMS

Low Report

Rating for NAMS

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.